军事知识服务平台
人类白细胞抗原分型与人类白细胞抗原抗体检测应用于器官移植术后临床输血及治疗的一例报告
A case report on the application of human leukocyte antigen typing and human leukocyte antigen antibody detection in clinical blood transfusion and treatment after organ transplantation
摘要 终末期肺病患者肺移植术后抗体介导的排斥反应(antibody-mediated rejection,AMR)是影响移植物存活的核心危险因素,供者特异性抗体(donor-specific antibody,DSA),尤其移植后新生DSA(de novo donor-specific antibody,dnDSA)是诱发排斥反应的关键诱因.本文回顾1例35岁终末期肺病患者双侧肺移植的临床资料,分析人类白细胞抗原(human leukocyte antigen,HLA)分型与HLA抗体动态检测在患者术后免疫监测、输血管理及排斥反应干预中的临床价值.患者既往有急性T淋巴细胞白血病骨髓移植病史,长期肺部病变进展至终末期肺病,符合肺移植手术指征,行全麻VV-ECMO辅助下双侧肺移植术.术后动态监测HLA抗体,检出预存及dnDSA,输血科及时预警并协助临床制定血浆置换、免疫抑制调整等个体化治疗方案.经3次分层血浆置换及对症抗排异治疗后,患者dnDSA完全清除,预存DSA持续低水平稳定,排斥反应风险得到有效控制.围术期全程HLA分型与抗体动态监测可精准识别移植术后免疫致敏状态、指导血浆置换时机与疗程、评估治疗效果,同时助力免疫抑制方案个体化调整.输血科参与移植术后免疫监测与多学科协作,可有效降低AMR发生风险,保障输血安全与移植预后,推动输血科从传统血液供应向移植免疫精细化管理转型,具有重要的临床推广价值.
Abstract:
Antibody-mediated rejection(AMR)after lung transplantation was a core risk factor affecting graft survival in patients with end-stage lung disease.Donor-specific antibody(DSA),especially de novo DSA(dnDSA),serves as a crucial trigger for rejection.This study retrospectively reviewed the clinical data of a 35-year-old patient who underwent bilateral lung transplantation for end-stage lung disease,and analyzed the clinical value of dynamic human leukocyte antigen(HLA)typing and HLA antibody detection in postoperative immune monitoring,blood transfusion management,and rejection intervention.The patient had a history of bone marrow transplantation for acute T-lymphoblastic leukemia,and progressive long-term pulmonary lesions progressed to end-stage lung disease,meeting the indications for bilateral lung transplantation under general anesthesia with VV-ECMO assistance.Postoperative dynamic HLA antibody monitoring identified preformed and dnDSA.The blood transfusion department issued timely risk warnings and assisted in formulating individualized therapeutic strategies including plasma exchange and immunosuppressive regimen adjustment.After three stratified sessions of plasma exchange and targeted anti-rejection therapy,the dnDSA was completely eliminated,the preformed DSA remained stably at a low level,and the risk of rejection was effectively controlled.This case confirms that perioperative whole-course HLA typing and dynamic antibody monitoring can accurately identify postoperative immune sensitization status,guide the timing and course of plasma exchange,evaluate therapeutic efficacy,and facilitate individualized adjustment of immunosuppressive regimens.Participation of the blood transfusion department in postoperative immune monitoring and multidisciplinary collaboration can effectively reduce the incidence of AMR,ensure blood transfusion safety and optimize transplantation prognosis,and promote the transformation of the blood transfusion department from traditional blood supply to refined transplantation immune management,which possesses important clinical promotional value.
刊 名 北京医学 ISTIC
年,卷(期): 2026, 48(8)
机标分类号: R392 R457.1 R617
在线出版日期: 2026年11月9日
基金项目: 2025-NHLHCRF-XKJS-B-06:中日友好医院中央高水平医院临床业务费,